AMSBIO has announced new additions to its portfolio of tools for COVID-19 research—two monoclonal antibodies that recognize the Spike RBD (B.1.1.529, Omicron Variant) protein and neutralize its interaction with ACE2. The new Spike neutralizing monoclonal antibodies (clone G10xA5 and G10xA1) recognize the SARS-CoV-2 Spike RBD (B.1.1.529, Omicron Variant) protein and neutralize its interaction with ACE2. Both of these neutralizing antibodies have been functionally tested using the Spike S1 RBD (B.1.1.529, Omicron Variant) (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit.